- Design
- Randomised, open-label phase II trial
- Population
- 41 untreated patients with limited-stage small cell lung cancer, China
- Primary outcome
- One-year progression-free survival
- Effect
- 65.5% vs 47.4% (p = 0.029); median PFS 24.0 vs 11.8 months
This randomised phase II trial in China enrolled 41 previously untreated patients with limited-stage small cell lung cancer between 2020 and 2024. One group had induction camrelizumab with etoposide-platinum, then concurrent chemoradiotherapy, then camrelizumab consolidation; the other had induction chemotherapy and concurrent chemoradiotherapy alone. The primary endpoint was one-year progression-free survival.
At a median follow-up of 32 months, one-year PFS was 65.5% with camrelizumab against 47.4% (p = 0.029), and median PFS 24.0 against 11.8 months. Median overall survival was not reached against 23.9 months (p = 0.042). All patients in the camrelizumab group responded. Severe immune-related adverse events occurred in 4.8%, and radiation pneumonitis was similar between arms.
The control arm had no immunotherapy consolidation, which is now standard after chemoradiotherapy for limited-stage disease, so the trial does not test whether adding PD-1 blockade at induction improves on today's standard. With 41 patients, the estimates are fragile. Camrelizumab's availability and approval status outside China vary and are not established here for India.
- Consolidation immunotherapy after chemoradiotherapy is the current standard comparator for limited-stage SCLC; this trial's control arm lacked it.
- The added benefit of PD-1 blockade during induction remains unproven against modern standard care.
- Severe immune-related adverse events were uncommon at 4.8% in this small sample.
- Radiation pneumonitis was not increased by combining camrelizumab with chemoradiotherapy.
- Consider trial enrolment for fit patients with limited-stage SCLC where available.
Why it matters
It suggests immunotherapy may help earlier in limited-stage SCLC than the consolidation phase where it is now used.
Don't overread it
The comparator lacked standard consolidation immunotherapy, and the trial is far too small to establish an overall survival benefit.
The statistics, in plain English
With 41 patients, one or two events can move the percentages a lot, and the confidence intervals around these estimates will be wide. Phase II gains of this size frequently shrink in phase III.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for oncology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free